-
Mashup Score: 100
Jean M. Connors, MD, Dana-Farber Cancer Institute and Amy E. DeZern, MD, MHS, Johns Hopkins University No relevant conflicts of interest to declare. This highly anticipated session highlights the Joint Program Committees’ selections of the highest-impact abs tracts, featuring substantive, novel, and groundbreaking data that were not available by the general abstract submission deadline and would otherwise not be presented at the ASH annual
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0Webprogram Unavailable - 2 month(s) ago
Please click HERE if you are not redirected in 5
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Webprogram Unavailable - 2 month(s) ago
Please click HERE if you are not redirected in 5
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Frontline ibrutinib for younger patients with MCL: Results from the phase III TRIANGLE trial - 3 month(s) ago
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, Martin Dreyling presented results from the phase III TRIANGLE trial as part of the plenary scientific session.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Variability of definition of high‐risk multiple myeloma across phase III clinical trials - 3 month(s) ago
eJHaem is a Gold open access haematology journal of the British Society for Haematology, publishing practice and research papers applicable to a worldwide readership.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Ajai Chari, MD, Discusses the MonumenTAL-1 Study - 4 month(s) ago
Talquetamab “demonstrated robust effic acy and manageable safety” in patients with heavily pretreated relapsed or refractory multiple myeloma, according to results from the phase I/II MonumenTAL-1 study. Ajai Chari, MD, of Mount Sinai School of Medicine, presented the data on talquetamab, a bispecific antibody targeting CD3 and GPRC5D, during the 2022 American Society of Hematology (ASH) Annual Meeting. “The MonumenTAL-1 study is really exciting,” Dr. Chari said, noting the phase I portion of the study
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 2
This provides reassurance that long-term lenalidomide treatment is safe and associated with improved outcomes in TE and TNE populations, although monitoring for SPM development should be incorporated into clinic review processes.
Source: www.thelancet.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 02023 ASH ALL Inotuzumab Update [Slides] - Van Huynh, MD MOASC - 4 month(s) ago
Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia that was presented at ASH in New Orleans. So I think there were so many great talks. There were so many great talks and I decided I would focus on just three and really…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚀 #ASH22 Updates in ALL Immunotherapy with Inotuzumab! Van Huynh, MD @MOASC_Office @UCIrvineHealth, shared insights at #MOASC23. 🩺 Discover remarkable breakthroughs![Video]🎥: https://t.co/BBlUqPvBAS 💊 #oncology #leukemia #medicalresearch #Immunotherapy #UCIMedSchool #CARTcell https://t.co/OSKdxJCTLI
-
-
Mashup Score: 1Elranatamab for RRMM: Updates from the MagnetisMM trials - 4 month(s) ago
Here, we summarize the latest data from the MagnetisMM trials of elranatamab for relapsed/refractory multiple myeloma in both BCMA-exposed and BCMA-naïve patients.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0TRIANGLE Trial Results Support First-Line Ibrutinib Use in MCL - 4 month(s) ago
High-dose cytarabine-containing immunochemotherapy followed by autologous hematopoiet ic stem cell transplantation (AHSCT) “failed to show superiority over” an ibrutinib-containing treatment without AHSCT in patients with mantle cell lymphoma, according to results from the phase III TRIANGLE trial. Martin Dreyling, MD, of the LMU University Hospital Munich in Germany, and colleagues conducted the study and presented its results at the 2022 American Society of Hematology Annual Meeting. The European MCL
Source: bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet
Dara RVd superior to RVd for PFS in newly diagnosed transplant eligible myeloma! #ASH22 As of now any randomized trials using triplets as control arm in newly diagnosed transplant eligible myeloma is unfair to patients. Late-Breaking Abstracts https://t.co/oiQ8dwcPCc